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Abstract The transport mechanism by which the multidrug
resistance protein 1 (MRP1) effluxes cytotoxic agents out of
cells is still not completely understood. However, the cellular
antioxidant glutathione (GSH) has been shown to have an
important role in MRP1-mediated drug transport. In this study
we show that GSH stimulates the ATPase activity of MRP1 in a
natural plasma membrane environment. This stimulation was
dose-dependent up to 5 mM. The MRP1 substrates vincristine
and daunorubicin do not induce MRP1 ATPase activity. In
addition, the effect of GSH on the MRP1 ATPase activity is not
increased by daunorubicin or by vincristine. In contrast, a GSH
conjugate of daunorubicin (WP811) does induce the ATPase
activity of MRP1. In the presence of GSH the effect of WP811
was not significantly increased. Finally, (iso)flavonoid-induced
MRP1 ATPase activity is not synergistically increased by the
presence of GSH. In conclusion, we show that GSH has no
apparent influence on the ATPase reaction induced by several
MRP1 substrates and/or modulators. The subclasses of mole-
cules had different effects on the MRP1 ATPase activity, which
supports the existence of different drug binding sites.
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1. Introduction
ATP-dependent transport proteins play an important role
in biology and medicine. A variety of ABC transporters have
been characterized [1]. Several of these proteins can cause
cellular resistance against natural toxins or toxic agents used
in medicine. One transporter protein is the MRP-1-encoded
multidrug resistance protein 1 (MRP1) [2,3]. Overexpression
of MRP1 causes so-called multidrug resistance (MDR) [4],
which may contribute to less e¡ective chemotherapeutic treat-
ment of diseases.
In recent years, the substrate speci¢city of MRP1 has been
the topic of intensive research. MRP1 appeared to mediate the
transport of a broad range of drugs across cellular membranes
[5,6], and has been characterized as a transporter of neutral
and anionic compounds, such as glutathione-conjugated
drugs, sulfates and glucuronides [4,7]. In addition, antifolates,
such as the anticancer agent methotrexate, were recently de-
scribed as MRP1 substrates [8]. Therefore, MRP1 is consid-
ered to be a multiple organic anion transporter [7,9].
The main cellular antioxidant glutathione (GSH) has been
reported to have an important function in MRP1 activity. The
presence of millimolar levels of cellular GSH has turned out
to be necessary for MRP1-mediated e¥ux of cytotoxic agents,
such as the anthracyclines [10,11]. Several other observations
have led to the assumption that potential MRP1 substrates
have to form conjugates with GSH, in order to make their
transport by MRP1 possible [7,9,12^14]. Therefore, MRP1
has been considered a member of the GS-X pump family
[15]. Alternatively, GSH has been described as a required
co-substrate, which would be transported concomitantly
with MRP1 substrates [16^19].
Available evidence suggests that transmembrane domains as
well as cytoplasmic domains of MRP1 may recognize MRP1’s
various hydrophobic and hydrophilic substrates [20]. In anal-
ogy to P-glycoprotein (Pgp), the ATP hydrolysis necessary for
transport is supposed to be carried out at nucleotide binding
domains in MRP1. Also, in the light of recent studies of the
action of potential substrates on the ATPase reaction of
MRP1 [21^24] it appears that several GSH-conjugated com-
pounds, such as dinitrophenyl S-glutathione, as well as several
unconjugated compounds, such as (iso)£avonoids, are able to
interfere with MRP1 ATPase activity. The role of GSH itself
in MRP1-associated ATPase activity has been studied in two
articles, in which puri¢ed MRP1 was reconstituted into arti-
¢cial lipid membranes [23,24]. In those papers, however, con-
£icting data were presented concerning the induction of AT-
Pase activity by reduced GSH. As indicated by one of the
authors the lipid environment might be of in£uence on the
ATPase activity of MRP1 [24] and, consequently, on the out-
come of these studies. This has earlier been demonstrated for
Pgp-associated ATPase activity [25]. Therefore, it seems of
great importance to study MRP1-associated ATPase activity
in reconstituted lipids as well as in a natural membrane envi-
ronment.
In the present work we investigated the role of GSH in
facilitating MRP1-mediated drug transport at the level of
the ATPase reaction of MRP1. In brief, we studied the e¡ects
of GSH on MRP1 ATPase in its natural (lipid) environment.
The e¡ects of several established MRP1 substrates, such as
daunorubicin (DNR), vincristine (VCR), and a DNR^GSH
conjugate (WP811) on MRP1 ATPase activity were investi-
gated. In addition, we have determined the e¡ect of GSH on
(iso)£avonoids^MRP1 interactions. (Iso)£avonoids, among
which the currently tested anticancer agent £avopiridol [26],
are among the ¢rst identi¢ed inhibitors of MRP1-mediated
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drug transport, and also increase MRP1 ATPase activity
[21,22,27,28]. Therefore, we included these compounds to an-
alyze drug^MRP1 interactions.
2. Materials and methods
2.1. Chemicals
The synthetic £avone derivative £avopiridol (L86-8275, NSC
649890) (3)cis-5,7-dihydroxy-2-(2-chlorophenyl)-8[4-(3-hydroxy-1-
methyl)-piperidinyl]-4H-benzopyran-4-one was kindly provided by
Dr. Bolen (Hoechst Marion Roussel, Cincinnati, OH, USA). Reduced
GSH, malachite green base, ammonium molybdate, probenecid, benz-
bromarone, Triton N101, digitonin, ATP, verapamil hydrochloride,
dithiothreitol (DTT) and the £avonoid kaempferol were from Sigma
(St. Louis, MO, USA). The £avonoid apigenin was from Extrasynth-
ese (Genay, France). The iso£avonoid genistein was from ICN Bio-
medicals (Zoetermeer, the Netherlands). The (iso)£avonoids were dis-
solved as a stock solution of 40 mM in DMSO (Across Chimica,
Belgium) and stored at 320‡C. Before experiments 1:1 dilutions
were made in ethanol, followed by dilution in ethanol/water (1:3,
v/v) to the appropriate concentrations. The maximal concentration
of DMSO and ethanol, which was also added to the controls, was
0.5% (v/v). Daunorubicin hydrochloride was from Specia (Paris,
France). The GSH conjugate of daunorubicin, WP811, was synthe-
sized as described earlier [29]. WP811 was dissolved in DMSO (100
mM) and stored at 320‡C. Doxorubicin hydrochloride was from
Laboratoire Roger Bellon (France).
2.2. Cell lines
The human small cell lung cancer cell line GLC4 and its adriamy-
cin-selected MRP1-overexpressing subline GLC4/ADR [30], as well as
the human ovarian carcinoma cell line 2008 and its stable MRP1
transfectant 2008/MRP1 (clone 4) [31], were cultured in RPMI 1640
medium (Flow Labs., Irvine, UK), supplemented with 10% (v/v) heat-
inactivated fetal calf serum (Gibco, Paisley, UK). GLC4/ADR cells
were cultured in the presence of 1.2 WM doxorubicin until 7^14 days
before the experiments. As reported earlier, all of these cell lines do
not express the MRP homologues MRP2^5 or MDR1^3 [32].
2.3. Antibodies
The preparation of the monoclonal antibody MIB6, against MRP1,
has been described elsewhere ([22] and Sche¡er et al., in preparation).
MIB6 has been reported to speci¢cally inhibit MRP1-associated ATP-
ase activity, as well as MRP1-mediated drug transport into inside-out
membrane vesicles.
2.4. Plasma membrane vesicles
Plasma membrane vesicles were prepared as described earlier [33].
First, cells were harvested by centrifugation (275Ug, 5 min) and sub-
sequently washed in phosphate-bu¡ered saline. Cell pellets were re-
suspended in 100 mM KCl, 5 mM MgCl2, 1 mM phenylmethylsul-
fonyl £uoride and 50 mM HEPES^KOH (pH 7.4) for 1 h at 0‡C,
followed by ultrasonication at 20% of the maximum power of an
MSE sonicator (Soniprep 150) (three bursts of 15 s) Then, the sus-
pension was centrifuged at 1500Ug for 10 min. The post-nuclear
supernatant was layered on top of a sucrose cushion (46% m/v). After
ultracentrifugation (100 000Ug, 60 min) the interface was collected,
washed in 100 mM KCl^50 mM HEPES^5 mM MgCl2 bu¡er (pH
7.4) and ultracentrifuged again (100 000Ug, 30 min). The ¢nal mem-
brane preparation was resuspended in 100 mM KCl^50 mM HEPES^
5 mM MgCl2 bu¡er (pH 7.4) and stored at 380‡C at a protein con-
centration of V2 mg/ml.
2.5. ATPase activity determinations
ATPase activity of MRP was measured colorimetrically according
to a method described earlier [34] with some modi¢cations. Plasma
membranes prepared as described above were incubated for 1 h in
KCl^HEPES bu¡er (pH 7.4) at 37‡C, in the presence of 1 mM
EGTA, 1 mM sodium azide and 0.1 mM ouabain, with or without
1 mM ATP. During the incubation time the reaction was linear, as
was shown before [21]. Subsequently, a mixture of the color reagent
(0.034% w/w malachite green base, 1.05% w/w ammonium molybdate)
and 0.025% v/v Triton N101 was added. After 1 min sodium citrate
was added to a ¢nal concentration of 3.6% (w/w). Light absorption
was measured 30 min later in an ELISA reader at a wavelength of
595 nm.
3. Results
3.1. Dose-dependent induction of MRP1 ATPase activity by
GSH
In order to study the role of GSH in MRP1 ATPase activ-
ity, we ¢rst measured the concentration dependence of GSH-
induced MRP1 ATPase activity. We used membranes pre-
pared from the tumor cell line GLC4 and its MRP1-overex-
pressing subline GLC4/ADR, and from the tumor cell line
2008 and its MRP1 transfectant 2008/MRP1. Fig. 1 shows
the GSH induction of ATPase activity of 2008 and 2008/
MRP1 membranes and of GLC4 and GLC4/ADR mem-
branes. Clear GSH e¡ects were observed in membranes of
both the MRP1-overexpressing cell lines, whereas in mem-
branes of parental cells no or a very small ATPase stimulation
could be observed. A maximum induction of the ATPase ac-
tivity in MRP1-containing membranes was observed at a con-
centration of 5 mM GSH. At this concentration the phos-
phate production of 2008/MRP1 membranes was 5.9 þ 0.1
nmol/mg protein/min (i.e. 129% of the control) and of
GLC4/ADR membranes 7.5 þ 0.4 nmol/mg protein/min (i.e.
159% of the control). Above GSH concentrations of 20 mM
the basal ATPase activity of the membranes was inhibited
(not shown). In order to exclude e¡ects of GSSG, potentially
formed during incubation with GSH, the e¡ect of 1 mM DTT
on the MRP1 ATPase stimulation by 5 mM GSH was meas-
Fig. 1. GSH-induced ATPase activity of MRP1. A: ATPase activity of MRP1 in membranes from 2008 cells (open symbols) and of 2008/
MRP1 cells (¢lled symbols). B: ATPase activity of membranes from GLC4 cells (open symbols) and from GLC4/ADR cells (¢lled symbols).
Data are means þ S.D. (n = 3). ATPase activity is given as percentage of control (without GSH). Absence of error bars means that the S.D. is
smaller than the symbol.
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ured. In the presence of DTT no signi¢cant di¡erence with the
e¡ect of GSH alone was observed (data not shown).
3.2. Inhibition of GSH-induced MRP1 ATPase activity
As shown above, GSH-induced ATPase activity was meas-
ured using membranes prepared from the MRP1 transfectant
cell line 2008/MRP1, and not in membranes from parental
2008 cells, which indicates the MRP1 speci¢city of this e¡ect.
However, since the MRP1 overexpression and accordingly the
MRP1-associated ATPase activity was much higher in mem-
branes from GLC4/ADR cells, we selected this cell line for
further studies. In order to obtain more evidence for the
MRP1 speci¢city of the GSH e¡ect in GLC4/ADR, we used
the earlier described MRP1 antibody MIB6 [22] to speci¢cally
inhibit MRP1 ATPase activity. As shown in Table 1, MIB6
was able to inhibit the GSH-induced ATPase activity of
GLC4/ADR membranes. Also, we tested whether we could
inhibit this GSH-induced ATPase activity with the earlier de-
scribed inhibitors of MRP1-mediated drug transport benzbro-
marone [35] and probenecid [36]. Benzbromarone inhibited
the stimulation of ATPase activity by GSH in 2008/MRP1
membranes (not shown) and GLC4/ADR membranes (Table
1) completely. Interestingly, probenecid did not inhibit the
GSH-induced ATPase activity. In contrast, probenecid stimu-
lated MRP1 ATPase activity in the absence or presence of
GSH. In membranes prepared from the parent cells no stim-
ulation by probenecid could be observed (data not shown).
3.3. Comparison of DNR and WP811 e¡ects on MRP1
ATPase activity
In order to study possible interactions of GSH with MRP1
substrates, we chose to use the established MRP1 substrate
DNR. We measured the ability of DNR to induce MRP1
ATPase activity. Also, we compared the e¡ect of DNR on
ATPase activity with the DNR^GSH conjugate WP811 [29],
since many drug^GSH conjugates have been suggested to be
preferred MRP1 substrates [7,9,12,13]. In Fig. 2 the induction
of ATPase activity in the presence of di¡erent concentrations
of both compounds is given. In contrast to DNR, which did
not have an e¡ect up to 50 WM, WP811 induced ATPase
activity to a signi¢cant level at concentrations above 20 WM.
A maximum WP811 e¡ect occurred at a concentration of
30 WM WP811.
3.4. Induction of the MRP1 ATPase by MRP substrates in the
presence of GSH
Recently, it has been reported that GSH may act as a co-
substrate in MRP1-mediated transport of several anticancer
agents, including VCR [16] and DNR [17]. This suggests that
the presence of GSH is needed to allow e⁄cient interaction of
MRP1 with substrates leading to their transmembrane trans-
port. Thus, we measured the ATPase e¡ect of simultaneous
incubation of GSH with DNR, VCR and WP811 (Fig. 3).
Again WP811 induced the ATPase activity to a signi¢cant
level, and in the presence of 0.5 mM or 5 mM GSH no
increase of the ATPase activity was observed for WP811,
DNR or VCR.
3.5. Induction of the MRP1 ATPase by (iso)£avonoids in the
presence of GSH
As described earlier, several (iso)£avonoids are able to in-
duce MRP1 ATPase activity [22]. Therefore, we also investi-
gated the e¡ect of GSH on £avonoid-induced MRP1 ATPase
activity. In particular, we studied the e¡ect of 0.5 mM and
5 mM GSH on the induction of MRP1 ATPase activity by the
(iso)£avonoids genistein, apigenin and £avopiridol (Fig. 4).
Table 1
Inhibition of GSH-induced MRP1 ATPase activity of GLC4/ADR
membranes
Substrate MRP1 ATPase activity (% of control)
Control 100
GSH 132 þ 4*
GSH+MIB6 110 þ 8#
Benzbromarone 86 þ 5
GSH+benzbromarone 91 þ 9#
Probenecid 124 þ 9*
GSH+probenecid 144 þ 6*#
Concentration of GSH was 1 mM, concentration of MIB6 was 0.35
Wg/ml, concentration of benzbromarone was 100 WM and concentra-
tion of probenecid was 500 WM.
*Signi¢cant di¡erence from the control (Student’s t-test, P6 0.05;
n = 6).
#Signi¢cant di¡erence from the GSH e¡ect (Student’s t-test, P6 0.05;
n = 6).
Fig. 2. Induction of MRP1 ATPase activity by DNR and the
DNR^GSH conjugate WP811. ATPase activity of GLC4/ADR
membranes was measured in the presence of 10, 20, 30, 40 or 50
WM DNR (open symbols), or WP811 (same concentrations) (closed
symbols). Data are means þ S.D. (n = 3). Symbols labeled with an
asterisk are statistically di¡erent from control (100%), as calculated
with Student’s t-test (P6 0.05, n = 3). Absence of error bar means
that the error bar is within the symbol.
Fig. 3. E¡ect of GSH on the interaction of DNR, VCR and WP811
with MRP1. MRP1 ATPase activity of GLC4/ADR membranes was
measured in the presence of 30 WM VCR, DNR or WP811 without
GSH (open bars), in the presence of 0.5 mM GSH (hatched bars),
or in the presence of 5 mM GSH (¢lled bars). Data are
means þ S.D. (n = 7). Bars labeled with an asterisk are signi¢cantly
di¡erent from 100% (P6 0.05, n = 7).
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All tested (iso)£avonoids induced the ATPase activity in the
absence of GSH. In the presence of GSH the induction of
ATPase activity was comparable with the GSH controls.
There was no indication for an additive or synergistic increase
of the MRP1 ATPase activity.
4. Discussion
The multidrug resistance protein MRP1 is a member of the
family of ABC transporters [1^3]. Hydrolysis of ATP is re-
quired for the transport activity of this protein. MRP1 has
been shown to transport major anticancer agents, such as the
anthracyclines, vinca alkaloids and etoposide [4,15,27]. Re-
cently, antifolates have also been described as MRP1 sub-
strates [8].
The cellular antioxidant GSH has been shown to play an
important role in the transport mechanism of MRP1. Cellular
depletion of GSH abolishes the MRP1-mediated e¥ux of neu-
tral and basic drugs [11], and several studies have provided
evidence that MRP1 mediates drug transport with GSH act-
ing as a co-substrate [14,16,17]. Also, transport of drugs as a
GSH conjugate has been published [7,9,12^14]. However, re-
cently several GSH-independent interactions of MRP1 have
also been reported. The MRP1-mediated transport of antifo-
lates [8] and the induction of the MRP1 ATPase activity by
(iso)£avonoids [21,22], both in the absence of GSH, showed
that the presence of GSH is not absolutely required for MRP1
function.
Here we report an analysis of the e¡ects of GSH on the
induction of ATPase reactions associated with MRP1. We
focussed on the in£uence of GSH on MRP1 in its natural
lipid environment, and studied its interactions with several
established anticancer drugs and (iso)£avonoids.
Although earlier reports described ATPase activity of partly
puri¢ed MRP1, which was solubilized in lipids [23,24], we
chose to study MRP1 ATPase activity in a more physiological
environment. The necessity to provide an experimental basis
for the study of these interactions by using natural mem-
branes is very clearly shown for Pgp in which the ATPase
activity is signi¢cantly in£uenced by subtle di¡erences in the
lipid environment [26]. Moreover, con£icting data between
two recent reports on ATPase activity of puri¢ed and recon-
stituted MRP1 were explained by the authors as a possible
result of the arti¢cial lipid environments of MRP1 in those
studies [23,24]. Therefore, in our study we have used plasma
membrane fractions of MRP1-overexpressing cell lines.
Our data clearly show a GSH-induced MRP1-speci¢c ATP-
ase activity that was dose-dependent. The e¡ect of GSH on
the MRP1 ATPase was induced by concentrations in the milli-
molar range, which is in accordance with results by others,
who showed that 0.5 mM reduced GSH was able to induce
ATPase activity of partly puri¢ed MRP1 [23]. Also, drug
transport into MRP1-containing membrane vesicles has pre-
viously been described to be stimulated by millimolar concen-
trations of GSH [16,17]. Moreover, such GSH concentrations
are present in intact cells, and a lowering of this GSH con-
centration leads to a decreased drug e¥ux [11].
A main item we have addressed in this study is whether
interactions between GSH and putative or established
MRP1 substrates can be seen at the level of ATPase activity.
Recently, interactions between VCR or DNR and GSH have
been shown in transport assays using inside-out membrane
vesicles, in which MRP1-mediated transport of VCR or
DNR was stimulated by GSH [16,17]. Also, co-transport of
GSH with MRP1-mediated e¥ux of etoposide has been dem-
onstrated in intact cells [19]. Yet, despite these reported ob-
servations we found no evidence for the interaction of VCR
or DNR with GSH on the level of MRP1 ATPase activity.
Interestingly, and in contrast to VCR and DNR, some in-
hibitors of MRP1-mediated transport did stimulate the MRP1
ATPase activity. As described already in a study of (iso)£a-
vonoids [21], probenecid and the DNR^GSH conjugate
WP811 also induced MRP1 ATPase activity. Yet, like VCR
and DNR, these compounds apparently showed no synergistic
increase of their induced MRP1 ATPase activity in the pres-
ence of a millimolar GSH concentration.
A third category of MRP1-interacting compounds in our
study is presented by benzbromarone. This drug is a potent
inhibitor of the MRP1 ATPase activity induced by all putative
substrates or modulators tested so far. Benzbromarone does
not seem to a¡ect the basal ATPase activity.
With regard to MRP1 interactions of putative substrate/
modulator drugs and GSH, the present experiments do not
provide evidence that GSH facilitates or increases the ATPase
stimulation by these drugs. On the other hand, the clear in-
duction of ATPase activity by the DNR^GSH conjugate
WP811 in a micromolar concentration range adds further evi-
dence to the ¢nding that preferred substrates of MRP1 con-
tain a hydrophobic as well as a negatively charged part.
WP811 was earlier described as an inhibitor of MRP1-medi-
ated transport [29]. Priebe et al. reported that, in contrast to
Fig. 4. E¡ect of GSH on (iso)£avonoid-induced MRP1 ATPase ac-
tivity. ATPase activity of GLC4/ADR was measured in the presence
of 50 WM of the (iso)£avonoids £avopiridol (FPL), genistein (GNE)
or apigenin (APG), in the absence (open bars) or presence 5 mM
GSH (¢lled bars). Data are means þ S.D. (n = 3). All e¡ects were
signi¢cantly di¡erent from the control (100%). All (iso)£avonoid ef-
fects in the presence of GSH were not statistically di¡erent from
GSH e¡ects as calculated with Student’s t-test (P6 0.05, n = 3).
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DNR, WP811 was able to inhibit the MRP1-mediated uptake
of LTC4 into inside-out membrane vesicles. The competitive
inhibition by WP811 of MRP1-mediated LTC4 transport in
turn suggests that WP811 is an MRP1 substrate itself, that
has no need of additional GSH. That observation would be
consistent with our ¢nding of ATPase induction of MRP1 by
WP811 and the absence of a synergistic e¡ect by GSH.
In order to summarize the present data, it may be helpful to
discuss the analogies with or di¡erences from the much more
studied Pgp ATPase activity. First, Pgp is likely to have a
high basal ATPase activity, suggesting no rigid coupling of
ATP hydrolysis and drug transport [37]. This might explain
the rather small ratio of drug-induced Pgp ATPase activity to
basal Pgp ATPase activity as found in most studies [38]. In
this respect, there may be a parallel between Pgp and MRP1
for substrates such as the anthracycline DNR; in neither case
does the substrate induce a stimulation or inhibition of the
ATPase activity ([39] and this study).
Further, the concentration-dependent pattern of MRP1
ATPase induced by, for example, WP811 and GSH is very
similar to that seen in most Pgp studies [38,40,41]. In addition,
we were not able to observe an increase of MRP1 ATPase
activity induced by GSH in the presence of the substrates
DNR or VCR. Similar observations have previously been re-
ported for Pgp, in which even an inhibition of ATPase activity
was observed upon simultaneous incubation of an ATPase-
activating modulator and an established Pgp substrate [42].
Several models of Pgp binding have been proposed for the
localization of the drug binding sites in Pgp, all of which
shared the feature of having at least two drug binding sites
[42,43]. In comparison, di¡erent drug binding sites have also
been shown to be involved in the interaction of MRP1 with
di¡erent subclasses of substrates [20]. Despite the limitations of
natural membrane preparations as well as puri¢ed systems we
think that ATPase studies may contribute to our understand-
ing of MRP1. However, it is clearly too early to explain the
present data or those of Chang et al. [23] and Mao et al. [24] in
terms of drug binding and transport properties of MRP1.
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